Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin
This article was originally published in The Pink Sheet Daily
Executive Summary
Arena and Eisai expect to hear in the next week or so whether FDA will accept their answer to an October 2010 “complete response” letter and set a new action date for their novel weight loss drug.
You may also be interested in...
Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors
Arena Pharmaceuticals gets new May 10 advisory committee review for its obesity therapy lorcaserin; execs say the recent positive review for competing Qnexa bodes well, and that this time around the risk/benefit profile for lorcaserin is much stronger.
Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs
Recent guidance on Orexigen’s Contrave could provide clues about how the agency is leaning on drugs in the highly safety conscious obesity category. New analysis of SCOUT data for Abbott’s withdrawn Meridia (sibutramine) could crop up in the discussion, former panelist says.
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.